- ►diabetesjournals.org N Hotta, Y Akanuma, R Kawamori, K Matsuoka, Y … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor nerve
conduction velocity (MNCV) ≥40 m/s, and HbA 1c ≤9% were enrolled in this open-label, multicenter
study and randomized to 150 mg/day epalrestat or a control group. After excluding the ... Cited by 46 - Related articles - BL Direct - All 5 versions
C Trial - Diabetes Care, 2006 - Am Diabetes Assoc The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes ... N IGISHI H OTTA
, MD 1 Y ASUO A KANUMA , MD 2 R YUZO K AWAMORI , MD 3 K EMPEI M ATSUOKA , MD
4 Y OSHITOMO O KA , MD 5 M OTOAKI S HICHIRI , MD 6 ... T AKAYOSHI T OYOTA , MD ... Related articles
V Bril, RA Buchanan - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Patients with mild to moderate DSP, as determined
by the presence of sural nerve responses, were enrolled in a double-blind, placebo-controlled
biopsy trial and randomized to placebo or 5 or 20 mg/day ranirestat for 12 weeks. Patients ... Cited by 45 - Related articles - BL Direct - All 6 versions
N Hotta, T Toyota, K Matsuoka, Y Shigeta, R Kikkawa, T … - Diabetes Care, 2001 - cat.inist.fr OBJECTIVE The purpose of this study was to evaluate the efficacy of fidarestat, a novel aldose
reductase BAR) inhibitor, in a double-blind placebo controlled study in patients with type 1 and
type 2 diabetes and associated peripheral neuropathy. RESEARCH DESIGN AND ... Cited by 63 - Related articles - BL Direct - All 5 versions
S Misawa, S Kuwabara, K Kanai, N Tamura, M Nakata, … - Neurology, 2006 - AAN Enterprises Methods: The authors conducted a 6-month, open clinical trial with an ARI, epalrestat, in 30 patients
with mild-to-moderate diabetic neuropathy. The latent addition technique and measurements
of the strength-duration time constant were used to estimate nodal persistent Na + ... Cited by 12 - Related articles - BL Direct - All 3 versions
V Bril, RA Buchanan - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE—The primary purpose of this investigation was to determine whether AS-3201,
a new aldose reductase inhibitor, penetrates the sural nerve and inhibits sorbitol and fructose
accumulation in patients with diabetic sensorimotor polyneuropathy (DSP). An additional ... Cited by 49 - Related articles - BL Direct - All 7 versions
K Uchida, T Kigoshi, S Nakano, T Ishii, M Kitazawa, S … - Clinical therapeutics, 1995 - Elsevier The effects of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy
were studied in 45 patients with non—insulin-dependent diabetes mellitus (NIDDM). Epalrestat
150 mg three times daily was given for 24 weeks. Subjective symptoms, such as ... Cited by 24 - Related articles - BL Direct - All 4 versions
Y Goto, N Hotta, Y Shigeta, N Sakamoto, R … - Biomedicine & …, 1995 - Elsevier The clinical efficacy of epalrestat (150 mg/day, 50 mg tid, po; A group), an aldose reductase
inhibitor, was evaluated in 196 patients with diabetic neuropathy by a double-blind study using
placebo (9 mg/day, 3 mg tid, po; P group) as a control for 12 weeks. The disappearance ... Cited by 30 - Related articles - All 4 versions
N Giannoukakis - Curr. Opin. Investig. Drugs, 2006 - 万方数据资源系统 Ranirestat is an orally available aldose reductase inhibitor under development by Dainippon
Sumitomo Pharma Co Ltd (formerly Dainippon Pharmaceutical Co Ltd), Kyorin Pharmaceutical
Co Ltd and Eisai Co Ltd for the potential treatment of diabetic complications, such as ... Cited by 8 - Related articles - BL Direct - All 4 versions
SR Sharma, N Sharma - Annals of Indian Academy of Neurology, 2009 - Medknow Ann Indian Acad Neurol, Official Journal of Indian Academy of Neurology.
Related articles - Cached - All 2 versions
